Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
A phase-II study showed that Siponimod has dose-dependent beneficial effects in patients with relapsing remitting disease. The results of a phase-III study suggest that Siponimod may be beneficial in secondary progressive Multiple sclerosis (MS), at least in patients with disease activity
Siponimod reduced the risk of disability progression with a safety profile similar to that of other Sphingosine 1-phosphate receptor modulators and is likely to be a useful treatment for secondary progressive [multiple sclerosis](brain://RygSvny9F…